Latest Healthcare News

Regis Healthcare reveals strong first-half FY25 financial results with rising occupancy and earnings, while gearing up for significant regulatory reforms under the new Aged Care Act effective July 2025.

Alterity Therapeutics is set to present compelling Phase 2 clinical trial results for ATH434 at the 2025 International Multiple System Atrophy Congress, highlighting slowed disease progression and biomarker engagement in MSA patients.

Mayne Pharma has announced the expiration of the US antitrust waiting period, a critical step forward in Cosette Pharmaceuticals' proposed acquisition. The transaction now moves closer to completion, pending other regulatory and shareholder approvals.

Echo IQ has raised $17.3 million through a strongly supported institutional placement to fund US commercialization and FDA approval efforts for its EchoSolv AI cardiology products.

Acrux Limited has appointed John Warmbrunn as its new CEO and Managing Director, signaling a strategic push for international expansion and product development starting June 2025.

CLINUVEL Pharmaceuticals has completed recruitment for its Phase III trial of SCENESSE® in vitiligo patients with darker skin types, setting the stage for first results in late 2026. Early clinical observations suggest promising repigmentation outcomes.

MedAdvisor Limited has received a non-binding offer from a major multinational software company to acquire its ANZ business division, valuing it above current market expectations.

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

EZZ Life Science Holdings Limited has announced a fully franked ordinary dividend of AUD 0.02 per share for the six months ending December 2024, signaling steady returns for shareholders.

Wellnex Life Limited announces key board and management changes following its successful AIM Market dual listing, including the resignation of its Non-Executive Chairman and appointment of a joint CEO to drive growth.

Biome Australia is expanding its health portfolio with Activated Therapeutics, a new practitioner-only brand launching four evidence-based natural medicine products in Q4 2025.

Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.